STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Steven Cohen’s Point72 Reports 3.34 M Verastem Shares in 13G Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Point72 discloses 6.1 % passive stake in Verastem (VSTM)

Schedule 13G dated 25 Jul 2025 reveals that Point72 Asset Management LP, its general partner Point72 Capital Advisors Inc., and founder Steven A. Cohen jointly hold 3,338,419 Verastem common shares—6.1 % of the outstanding class. The shares are owned through Point72 Associates, with Cubist Systematic Strategies acting as sub-advisor. All voting and dispositive authority is shared; none is held solely. The filing is under Rule 13d-1(b)/(c), signifying a passive investment, and includes a certification that the stake was not acquired to influence control.

Jason M. Colombo signed on behalf of all reporting persons on 28 Jul 2025. No derivatives or additional security classes are mentioned.

  • Shares owned: 3.34 M
  • Percent of class: 6.1 %
  • Reporting persons: Point72 Asset Management LP, Point72 Capital Advisors Inc., Steven A. Cohen
  • Intent: Passive (Schedule 13G)

Positive

  • Point72, led by Steven A. Cohen, accumulated 3.34 M shares (6.1 %) of VSTM, signalling institutional confidence and potential liquidity support.

Negative

  • None.

Insights

TL;DR: Point72’s new 6.1 % stake introduces a high-profile, deep-pocketed holder, potentially boosting market confidence without seeking control.

The disclosure positions Verastem among Point72’s portfolio companies, suggesting internal conviction in the biotech’s pipeline. Although 6.1 % is modest in absolute terms, the buyer’s reputation can attract co-investors and improve liquidity. Because the filing is a 13G, Point72 indicates a passive stance; therefore, immediate activist catalysts are unlikely. Still, passive holders sometimes convert to 13D if conviction grows, creating optionality for future engagement. From a valuation perspective, institutional ownership above 5 % can tighten the float, affecting supply-demand dynamics and volatility.

TL;DR: Routine compliance filing; passive classification minimizes governance impact but crosses key 5 % disclosure threshold.

The joint filing clarifies that voting power is shared among three related entities with no sole authority, reducing risk of hidden control efforts. The certification under Item 10 affirms the absence of control intent, aligning with good governance norms. While material as a statutory threshold event, the filing does not alter board composition or strategic direction today.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/28/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/28/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/28/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

How much of Verastem (VSTM) does Point72 own?

Point72 reports 3,338,419 shares, equal to 6.1 % of the company’s outstanding common stock.

Is the filing a Schedule 13D or 13G?

It is a Schedule 13G, indicating a passive investment rather than an activist intent.

Does Point72 hold sole voting power over the shares?

No. The filing shows 0 shares with sole voting power; all voting and dispositive power is shared.

When was the ownership threshold event for this filing?

The event date triggering disclosure is July 25, 2025.

Who signed the Schedule 13G on behalf of the reporting persons?

Jason M. Colombo signed for Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen on 28 Jul 2025.

What is the CUSIP number for Verastem’s common stock?

The CUSIP number disclosed is 92337C203.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

801.40M
70.82M
0.82%
89.08%
25.94%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM